Bavarian Biotech Report 2011/2012 (7MB) - Bio M

Contact:Kurt MartinJosef-Engert-Straße 9D-93053 RegensburgPhone: +49 (0) 89 95001711Fax: +49 (0) 89 9612087E-Mail: Kurt.Martin@hepacult.deInternet: www.hepacult.dehepacult GmbHBIOTECH PRECLINICAL SERVICESKeywords: Analytical Chemistry, Drug Development, Tissue Engineering / CellCulture, Clinical Research, Toxicology, Analysishepacult develops and markets cell culture technology based on humanliver cells and other human organs. The cell culture technology is used toprognose the metabolism of novel drugs and for the in vitro simulation ofliver dysfunctions. With their cutting edge cell and tissue products hepacultprovides to the scientific community and pharmaceutical industry an outstandingin vitro test system coming close to the human in vivo conditions.Animal experiments can be replaced to a large extent. Results gained duringthe preclinical stage with hepatocytes show a better prognostic value.Partially even the cost-intensive clinical experiments on humans and relatedrisks to humans can be reduced.Contact:Isabell RemusIndustriestr. 18D-83607 HolzkirchenPhone: +49 (0) 8024 908-0E-Mail: isabell.remus@sandoz.comInternet: www.hexal.deHexal AGPHARMA & CHEMICAL INDUSTRYKeywords: Drug Development, Peptide/Protein, Pharmacokinetics, 3 DStructural Analysis, Clinical ResearchHEXAL is the leading German generic manufacturer and belongs to theworldwide Sandoz Group with its headquarters in Holzkirchen, Bavaria.HEXAL brings biosimilars to the German market. Biosimilars are high-differentiatedproducts, based on very complex biological molecules. Biologics,or biopharmaceuticals, are medicines produced from living organisms usingbiotechnology techniques. Many biologics are recombinant proteins and aremanufactured using „recombinant DNA“ technology, a process that involvesinserting a specific gene into a host cell to produce a particular protein.These complex state-of-the-art molecules represent a distinct regulatoryclass of medicine compared to traditional, chemically synthesized medicines.In Germany HEXAL employs more then 4.000 people at six sites. Thecompany was founded in 1986 and merged with Sandoz in 2006.HolsboerMaschmeyer NeuroChemie GmbHBIOTECH THERAPEUTICS & DIAGNOSTICSContact:Ramona Maria FichtnerMaximilianstraße 13D-80539 MünchenPhone: +49 (0) 89 30622 455Fax: +49 (0) 89 30622 483E-Mail: info@hmnc.deInternet: www.hmnc.de70Keywords: Biomarker Discovery & Development, Laboratory, PersonalizedMedicine, Medicinal Chemistry, Drug DevelopmentHolsboerMaschmeyer NeuroChemie GmbH is a Munich-based biotech companyspecialised in research and development of new drugs against depressionand anxiety disorders, that was founded in December 2010. The companyutilizes research results for the development of new chemical structureswhich then become specifically acting drugs. Laboratory tests developed byHolsboerMaschmeyer NeuroChemie GmbH identify the specific diseasemechanism of the affected patient and thus allow an individual therapy. Thecombined application of laboratory tests and specific drugs improves thequality of the therapy: duration of disease is shortened for the benefit ofpatients and the savings for the health care system are considerable.